|
|
|
Volumn 9, Issue 3, 2006, Pages 168-170
|
|
HCV therapeutics. 11-15 December 2005, Big Island, HI, USA
a
a
TRANSGENE S A
(France)
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ALANINE AMINOTRANSFERASE;
ANA 975;
ANTIVIRUS AGENT;
DENDRITIC CELL VACCINE;
DNA VACCINE;
GI 5005;
HCV CHIMIGEN;
HEPATITIS C ANTIBODY;
HEPATITIS C VACCINE;
HEPAVAXX C;
IMMUNOGLOBULIN;
INNO 101;
INNOVAC C;
NEUTRALIZING ANTIBODY;
PROTEINASE INHIBITOR;
SCH 503034;
UNCLASSIFIED DRUG;
VALOPICITABINE;
VX 950;
HEPATITIS VACCINE;
ANTIBODY TITER;
CLINICAL PROTOCOL;
CLINICAL TRIAL;
CONFERENCE PAPER;
DISEASE MODEL;
DRUG SAFETY;
DRUG SCREENING;
FOLLOW UP;
HEPATITIS C;
HEPATITIS C VIRUS;
HUMAN;
IN VITRO STUDY;
INFECTION PREVENTION;
KIDNEY DYSFUNCTION;
NONHUMAN;
PATIENT MONITORING;
PROTECTION;
RANDOMIZATION;
VACCINATION;
VIRUS REPLICATION;
VIRUS VECTOR;
ANIMAL;
IMMUNOLOGY;
ANIMALS;
ANTIVIRAL AGENTS;
CLINICAL TRIALS;
DISEASE MODELS, ANIMAL;
DRUG EVALUATION, PRECLINICAL;
HEPACIVIRUS;
HEPATITIS C;
HUMANS;
VIRAL HEPATITIS VACCINES;
|
|
EID: 33644945037
PISSN: 13697056
EISSN: None
Source Type: Journal
DOI: None Document Type: Conference Paper |
|
Times cited : (1)
|
|
References (0)
|
